Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM-H014 for MASH
NCT07016633Phase 2Not yet recruiting
- Sponsor
- Changchun Intellicrown Pharmaceutical Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of IMM-H014 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Changchun Intellicrown Pharmaceutical Co., Ltd.. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
IMM-H014
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07016633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07016633.